VANCOUVER, British Columbia–(BUSINESS WIRE)–#antibodies–AbCellera, a leader in therapeutic antibody discovery from natural
immune systems, today announced it has entered into an agreement with
Gilead Sciences to support the discovery of therapeutic antibody
candidates for infectious diseases. AbCellera will apply its expertise
in single-cell screening of natural immune sources to generate rich
panels of antibody candidates for evaluation by Gilead. Under the
agreement, AbCellera will receive upfront and research payments and is
eligible to receive downstream clinical and commercial milestone
payments and royalties on net sales of products.
“AbCellera is dedicated to partnering with the most innovative companies
to discover breakthrough therapies, and we look forward to adding our
technology to Gilead’s early research efforts,” commented Carl Hansen,
President and CEO of AbCellera.
Leveraging a suite of proprietary technologies, AbCellera’s team can
interrogate millions of single B cells in a campaign, an approach that
has proven successful in identifying low-frequency subsets of antibodies
among large and diverse panels of binders. In this collaboration,
AbCellera will be looking for ultra-rare antibodies with specific
properties defined by Gilead, a challenging problem that demands
screening depths that are orders of magnitude higher than alternative
discovery approaches.
Over the past three years, AbCellera has successfully completed more
than 30 antibody discovery programs, including deals with seven global
pharmaceutical companies and top-tier public and venture-backed biotech
companies. Applying best-in-class technology and custom innovation to
each project, AbCellera enables programs for any target class, including
difficult multi-pass membrane proteins, and provides its partners with a
competitive advantage through superior diversity, speed, and quality.
About AbCellera Biologics Inc.
AbCellera is a privately held company that engages in partnerships to
discover and develop next-generation therapeutic antibodies. AbCellera’s
single-cell platform integrates end-to-end capabilities for therapeutic
antibody discovery through a combination of technologies including
proprietary immunizations, microfluidics, high-throughput imaging,
genomics, computation, and laboratory automation. Ultra-deep screening
of single B cells allows unprecedented access to natural immune
responses, enabling rapid isolation of large and diverse panels of
high-quality lead antibodies from any species, including humans. For
more information, please visit www.abcellera.com
and connect on LinkedIn
and Twitter
@AbCelleraBio.
Contacts
AbCellera:
Kevin Heyries, PhD
1.604.559.9005
bd@abcellera.com